Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2019 Oct 21;34(40):e261.
doi: 10.3346/jkms.2019.34.e261.

The Prevention of Contrast Induced Nephropathy by Sarpogrelate: a Prospective Randomized Controlled Clinical Trial

You Jeong Ki  1   2 , Sun A Kwon  1 , Hack Lyoung Kim  1   2 , Jae Bin Seo  1   2 , Woo Young Chung  1   3
Affiliations
Randomized Controlled Trial

The Prevention of Contrast Induced Nephropathy by Sarpogrelate: a Prospective Randomized Controlled Clinical Trial

You Jeong Ki et al. J Korean Med Sci. .

Abstract

Background: Although some strategies are used for prophylaxis of contrast induced nephropathy, their efficacy is not fully established. Sarpogrelate can relieve vasospasm and have anti-inflammatory action. This study examined whether sarpogrelate reduces the incidence of contrast induced nephropathy (CIN) or subsequent renal impairment during four weeks after coronary angiography compared with a control group.

Methods: Seventy-four participants with chronic renal failure were randomly assigned to the sarpogrelate or control group. Patients assigned to the sarpogrelate group received oral saporogelate from 24 hours before contrast exposure up to one month after contrast exposure. The primary outcome of this study was the incidence of CIN within 48 hours after exposure to the contrast agent.

Results: Thirty-one subjects in the control group and 35 subjects in the sarpogrelate group were used for the analysis. Cumulative CIN occurred numerically more at 48 hours in the sarpogrelate group and less at one month without statistical significance (11.4% vs. 6.5% at 48 hours and 11.4% vs. 16.1% at one month, respectively). Baseline renal function was similar in both groups, but the estimated glomerular filtration rate (eGFR) was lower in the sarpogrelate group at 12 and 48 hours compared with the control group (45.6 vs. 54.7 mL/min/1.73m²; P = 0.023 and 39.9 vs. 50.6 mL/min/1.73m²; P = 0.020, respectively). At one month, the eGFR became comparable between the two groups because the eGFR was aggravated in the control group and maintained in the sarpogrelate group.

Conclusion: This study failed to demonstrate that sarpogrelate has a renoprotective effect against contrast induced acute kidney injury.

Trial registration: ClinicalTrials.gov Identifier: NCT01165567.

Keywords: Contrast Nephropathy; Coronary Angiography; Renal Insufficiency; Sarpogrelate; Serotonin.

PubMed Disclaimer

Conflict of interest statement

The authors have no potential conflicts of interest to disclose.

Figures

Fig. 1
Fig. 1. Study flow.
CKD = chronic kidney disease, CAG = coronary angiography.
Fig. 2
Fig. 2. Serial estimated GFR changes and cumulative incidence of CIN or renal impairment between two groups. Line graph shows serial eGFR and bar plot indicates the cumulative CIN incidence.
eGFR = estimated glomerular filtration rate, CIN = contrast induced nephropathy. *Between two groups, P value < 0.05.
See this image and copyright information in PMC

References

    1. Weisbord SD, Chen H, Stone RA, Kip KE, Fine MJ, Saul MI, et al. Associations of increases in serum creatinine with mortality and length of hospital stay after coronary angiography. J Am Soc Nephrol. 2006;17(10):2871–2877. - PubMed
    1. Section 4: contrast-induced AKI. Kidney Int Suppl (2011) 2011;2(1):69–88. - PMC - PubMed
    1. Solomon R. Contrast-medium-induced acute renal failure. Kidney Int. 1998;53(1):230–242. - PubMed
    1. Mehran R, Nikolsky E. Contrast-induced nephropathy: definition, epidemiology, and patients at risk. Kidney Int Suppl. 2006;69(100):S11–5. - PubMed
    1. McCullough PA, Adam A, Becker CR, Davidson C, Lameire N, Stacul F, et al. Risk prediction of contrast-induced nephropathy. Am J Cardiol. 2006;98(6A):27K–36K. - PubMed

Publication types

Associated data